Clinical trials are not suitable to identify rare, potentially serious adverse effects of drugs, or to define their safety in high risk populations.
Artemisinin-based combination therapies (or ACTs) are considered safe, but there are concerns over their potential to cause damage to parts of the brain. There is also a concern about their safety in patients infected with HIV.
Collating safety data is a challenge in Africa, where most antimalarials are used and more vulnerable populations reside.
The Safety Data Collection Tools for Real-World Reporting developed by the ACT Consortium are the first step to providing more resources for researchers seeking user-friendly methods to evaluate antimalarial safety.
Please join our interactive webinar on the safety of artemisinin-based combination therapies (ACTs) on Tuesday 7 October 12:30-2:00PM BST.
Full details are available at www.actconsortium.org/webinars